SLN Silence Therapeutics Plc

TIDMSLN

RNS Number : 0422F

Silence Therapeutics PLC

15 February 2018

Additional listing

15 February 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 30,000 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 21 February 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of shares in issue, following admission, will be 70,021,624. The Company holds no shares in Treasury.

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser        Tel: +44 (0)20 
  and Broker)                             7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                        Tel: +44 (0) 
  Optimum Strategic Communications        20 3714 1788 
  Mary Clark/ Eva Haas/ Hollie Vile 
  silence@optimumcomms.com 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSGGUCGPUPRGCA

(END) Dow Jones Newswires

February 15, 2018 09:27 ET (14:27 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024